CF
ALNY icon

Cantor Fitzgerald’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cantor Fitzgerald’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,584
Closed -$250K – 258
2024
Q1 		$237K Buy
+1,584
New +$264K 0.06% 132

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cantor Fitzgerald's ALNY Position: Q2 2024 in Review

Cantor Fitzgerald sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 1,584 shares — an estimated $250K sold.

Cantor Fitzgerald first reported a position in ALNY in Q1 2024 and held it in 1 quarter. The position peaked at $237K in Q1 2024. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Cantor Fitzgerald reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 1,584 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $250K.
  • Cantor Fitzgerald first reported a position in Alnylam Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's Alnylam Pharmaceuticals position peaked at $237K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Cantor Fitzgerald's 13F filing for Q2 2024, filed 14 Aug 2024.